Akebia Therapeutics, Inc. (AKBA) Social Stream
AKEBIA THERAPEUTICS INC (AKBA) Price Targets From Analysts
Use the tables below to see what analysts covering AKEBIA THERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-05 | 4 | $8 | $2.75 | $5.937 | $1.13 | 425.4% |
| 2022-01-28 | 2 | $10 | $6 | $8 | $1.13 | 607.96% |
| 2022-03-02 | 3 | $10 | $6 | $8 | $1.13 | 607.96% |
| 2022-03-08 | 4 | $10 | $6 | $8 | $1.13 | 607.96% |
| 2022-03-31 | 7 | $2 | $2 | $2 | $1.13 | 76.99% |
| 2022-05-10 | 7 | $2 | $1 | $1.75 | $1.13 | 54.87% |
| 2022-05-16 | 6 | $2 | $1.25 | $1.75 | $1.13 | 54.87% |
| 2022-06-06 | 7 | $2 | $1 | $1.562 | $1.13 | 38.23% |
| 2023-03-10 | 5 | $2 | $1.25 | $1.75 | $1.13 | 54.87% |
| 2023-04-26 | 2 | $2 | $2 | $2 | $1.13 | 76.99% |
| 2023-05-26 | 3 | $2 | $2 | $2 | $1.13 | 76.99% |
| 2023-07-24 | 3 | $4 | $2 | $3 | $1.13 | 165.49% |
| 2023-08-25 | 3 | $4 | $2 | $3 | $1.13 | 165.49% |
| 2023-08-28 | 3 | $4 | $3.75 | $3.875 | $1.13 | 242.92% |
The Trend in the Analyst Price Target
Over the past 31 months, AKBA's average price target has gone down $3.12.
AKBA reports an average of 165.52% for its upside potential over the past 42 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-11-04 | 5 | 2 | 1.25 | 1.750 | 0.271 | 545.76% |
| 2023-04-26 | 2 | 2 | 2.00 | 2.000 | 0.793 | 152.21% |
| 2023-07-24 | 3 | 4 | 2.00 | 3.000 | 1.220 | 145.9% |
| 2023-08-25 | 3 | 4 | 2.00 | 3.000 | 1.150 | 160.87% |
| 2023-08-28 | 3 | 4 | 3.75 | 3.875 | 1.380 | 180.8% |
AKBA Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.67 | 2 | 0 | 1 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
AKBA's average broker recommendation rating improved by 0.66 over the prior 21 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- AKBA has a greater average analyst price target than 38.84% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, AKEBIA THERAPEUTICS INC's number of analysts covering the stock is higher than 251.29% of them.
- In terms of how AKEBIA THERAPEUTICS INC fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -318.2% of that group.
- AKEBIA THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 651.3% of Pharmaceutical Products stocks.
In the Pharmaceutical Products industry, EGRX, CPRX, and LXRX are the three stocks most similar to AKEBIA THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding AKBA using the data that counts. Try POWR Ratings for free.